I am sharing a compelling N=1 case study (35yo Caucasian male) regarding statin selection, specifically targeting the intersection of aggressive lipid lowering (a non-negotiable for me due to an active history of childhood coronary artery disease) and high-volume endurance performance.
The Initial Protocol & Systemic Friction
My initial lipid management protocol began with Atorvastatin 10mg, followed by a transition to Rosuvastatin 10mg (plus Ezetimibe 10mg in both cases). In both instances, the physiological and cognitive drag was immediate and severe. I experienced profound systemic fatigue and ‘brain fog’ that simply failed to dissipate for months.
Crucially, as a high-volume trail runner, my haemodynamics completely shifted. Within barely half an hour of steady-state running, I would systematically experience significant cardiac drift—a phenomenon I had never previously encountered, with all other control variables remaining strictly static.
By the second month, I developed persistent tendinitis, which seemed correlated as I have learnt how to run in a tendon-friendly-way over two decades of training. This structural inflammation remained entirely refractory to rest and deloading, which historically resolves any mechanical overload for me. It is worth noting that targeted supplementation with both CoQ10 and geranylgeraniol yielded absolutely zero mitigation of these muscular and tendinous side effects.
The Pharmacological Pivot
Faced with an unacceptable degradation in my athletic output and cognitive baseline, I executed a hard pivot. I engaged a new cardiologist and presented my transition to Pitavastatin 4mg as a fait accompli (still keeping Ezetimibe 10mg in parallel).
I was acutely aware of the primary clinical caveat: Pitavastatin’s efficacy profile has predominantly been validated in Asian populations. However, as a Caucasian male, the empirical outcome was nothing short of a pharmacological triumph.
The Resolution Timeline
The systemic clearance of my previous side effects was highly deterministic:
- Week 1: The brain fog and systemic fatigue completely lifted.
- Week 1: The anomalous cardiac drift during endurance runs vanished, returning my heart rate metrics to baseline (both perceived and categorically measured on Garmin).
- Week 2: The tendinitis suddenly ceased flaring and has since been on a fast, definitive mend while resuming full running volume (~4x pre-Pitavastatin switch)!
The Lipid Telemetry
The most compelling aspect of this N=1 trial is the hard data when mapped against my historical trajectory. Before pharmacological intervention, my unmedicated lipid baseline sat at an LDL of 1.87 mmol/L and an ApoB of 73.0 mg/dL. When introduced to standard therapy, both Atorvastatin and Rosuvastatin managed to pull my numbers down, but my LDL plateaued around 1.2 to 1.4 mmol/L and ApoB hovered between 41 and 51 mg/dL. Yet, on Pitavastatin 4 mg—despite the drug historically being studied primarily in Asian cohorts—my telemetry smashed past those previous floors: my LDL plummeted to 0.60 mmol/L, and my ApoB dropped to an unprecedented 37 mg/dL.
Conclusion
For athletes or highly active individuals experiencing muscular, tendinous, or cardiovascular friction from standard statin protocols, Pitavastatin seems to be an option that warrants serious consideration.
Even anyone else, the complete absence of systemic fatigue and brain fog makes it equally worthy of exploration.
In my personal case, it has delivered elite-tier lipid reduction with absolute zero physiological drag. Having found this equilibrium, I would not revert to another statin under virtually any circumstances.
).